环状软骨上喉次全切除术后喉功能探讨

目的 探讨环状软骨上喉次全切除术后喉功能的恢复。方法 分析2002-2004年行环状软骨上喉次全切除术21例喉癌患者,其中声门型14例,行环状软骨-舌骨-会厌固定术：声门上型7例,行环状软骨-舌骨固定术。结果 术后30-45天拔管,平均拔管时间为36．4天,拔管率为90．5％（19／21）;大多患者术后有误咽,经训练后全部恢复正常饮食及发音功能但有不同程度的嘶哑。结论 环状软骨上喉次全切除术是保留喉功能的有效术式。     

环状软骨上喉次全切除术及疗效分析

目的探讨环状软骨上喉次全切除术(简称环上喉次全切除术)的可行性及其疗效。方法回顾性分析1990—2001年43例行环上喉次全切除术的T1b～T4及术后放疗后复发的喉癌患者,声门上癌16例,声门癌21例,声门下癌2例;外院术后复发3例,放疗后复发1例。临床分级:T1b6例,T213例,T316例,T44例。应用3种不同的环上喉次全切除术进行治疗(17例行环上喉次全切除环舌骨固定术,24例行环上喉次全切除环舌骨会厌固定术,2例采用环上喉次全切除气管环舌骨会厌固定术)。16例患者辅以放疗。结果KaplanMeier法统计生存率,随诊中位时间57个月。全组总的3年累积生存率为90.7%,5年累积生存率83.7%。术后拔管率为95.3%(41/43)。保留双侧杓状软骨的拔管时间为14d,保留单侧杓状软骨的拔管时间为43d。术后8周评价误咽发生率为14.0%(6/43),切除会厌增加了术后的误咽及拔管时间(P<0.05)。结论环上喉次全切除术是一种在肿瘤根治和喉功能保全上能达到临床应用水平的术式。     

环状软骨上喉次全切除喉功能重建及疗效观察

目的探讨环状软骨上喉次全切除喉功能重建及疗效。方法回顾分析1998～2005年行环状软骨上喉次全切除并行喉功能重建18例,其中声门型癌12例,声门上型癌6例。采用环状软骨-舌骨-会厌固定术式（CHEP）11例;气管．环状软骨、舌骨会厌固定术式（TCHEP）1例;环状软骨-舌骨固定术式（CHP）6例。结果18例患者术后均拔管,拔管率100％。CHEP术式,拔管时间为14～18d,平均15d;TCHEP术式,拔管时间20d;CHP术式拔管时间18—25d,平均21d。全部病例术后恢复呼吸及发音功能,保留会厌（CHEP,TCHEP）术式,短期误咽发生率为41．6％;切除会厌的CHP术式误咽发生率为100％。按术后8周评价,保留会厌者均无误咽,而切除会厌者误咽发生率占33．3％。术后随访,3年生存率88．8％,5年生存率75％。结论根据喉癌发生的部位和累及的范围选择环状软骨上喉次全切除,采用不同术式和重建方法,既能良好地保留喉功能,又能完整地切除喉肿瘤,是值得推广的一种术式。     

喉环状软骨上部分切除术治疗喉声门上型癌

目的总结喉环状软骨上部分切除术治疗喉声门上型癌的疗效。方法对32例接受喉环状软骨上部分切除术(环状软骨舌骨固定术)治疗的喉声门上型癌病例进行随访和回顾性分析。结果本组T2、T3病例的3年生存率分别为85.7%(18/21)和66.6%(2/3),T2、T3病例的5年生存率分别为83.3%(5/6)和50%(1/2);所有患者术后都能发音,发音比较粗或沙哑,但能听懂;所有患者术后都有不同程度的误咽,经过练习96.8%的患者误咽克服,1例患者(3%)因术后始终无法克服误咽,改为喉全切除术;拔管率为100%。结论喉环状软骨上部分切除术手术操作简便,术后肿瘤学结果和功能结果满意,是治疗侵犯一侧或两侧声带的喉声门上型癌的有效术式。     

环状软骨上喉次全切除术及其疗效

目的 探讨环状软骨上喉次全切除术的可行性及其适应证。方法 选择自１９８８～１９９６年不宜行常规水平或垂直半喉部分切除术的Ｔ２和Ｔ３喉鳞癌患者２１例行环状软骨上喉次全切除术。声门上型９例,声门型１０例,跨声门型２例。临床分级：Ｔ２期１６例,Ｔ３期５例。手术切除范围;舌骨、甲状软骨板、会厌前间隙和声门旁间隙,保留环状软骨和至少一侧杓状骨或部分正常会厌软骨。吹功能重建主要采用环状软骨舌根（会厌舌根）吻合     

环状软骨上喉部分切除术的探讨

目的　通过对 18例喉癌患者的手术治疗 ,就环状软骨上喉部分切除术的有关问题进行探讨。方法　声门癌T1N0 M0 1例 ,T2 N0 M0 9例 ,T3N0 M0 2例 ,跨声门癌T3N1M0 3例 ,T3N2 M0 1例 ,T2 N0 M0 放射治疗后复发 1例 ,声门下癌T4N0 M0 1例 ;应用三种不同的环状软骨上喉部分切除术技术进行治疗。结果　 3年生存率 94 .4 %。所有患者均于术后第 7～ 4 2天 (平均 17天 )拔除气管套管 ,拔管率 10 0 % ;所有患者均在术后第 14～ 3 0天 (平均 2 2天 )拔除鼻饲管。术后所有患者均完全恢复了喉的发声、呼吸、吞咽及维持声门下压的生理功能。术后的发音情况也令人满意。结论　环状软骨上喉部分切除术打破了以往根据喉癌肿瘤临床分期决定喉部分切除与否的传统观点 ,为喉癌的手术治疗提出了一条新的术式。它在保证完整、安全有效地切除喉肿瘤病灶的同时 ,更加考虑到患者术后的功能及生存质量的改善 ,同时又能达到喉全切除术同样的局部控制率 ,值得推广应用     

扩大喉环状软骨上部分切除及喉功能重建术

目的:对扩大喉环状软骨上部分切除及喉功能重建术的手术方法、适应证及喉功能恢复情况等进行探讨。方法:2000~2005年对10例向声门前下侵犯达10~20mm的T3、T4喉癌患者施行扩大环状软骨上部分喉切除及喉功能重建术。结果:9例患者均无瘤生存并仍在随访中,1例患者术后4年颈部转移癌复发死亡。所有患者术后均恢复了正常的呼吸、吞咽及维持声门下压的功能,术后发声也令人满意。结论:只要严格掌握手术适应证,对部分向声门前下侵犯达10~20mm的喉癌患者实施治疗,该术式确实能取代全喉切除术。     

信息动态

环状软骨上喉部分切除术源于欧洲并广泛开展应用,其理论基础是环杓单位为喉功能解剖单位.环状软骨上喉部分切除术包括环状软骨上喉部分切除-环舌骨会厌吻合术(SCPL-CHEP)、环状软骨上喉部分切除-环舌骨吻合术(SCPL-CHP)和环状软骨上喉部分切除-气管环舌骨会厌吻合术(SCPL-TCHEP)3种术式.本文就环杓单位作为喉功能解剖单位在环状软骨上喉部分切除术中的应用加以论述.     

保留喉功能的T3期声门上喉癌的手术治疗

目的：探讨T3期声门上喉癌喉功能保留手术的可行性、技术操作和临床疗效。方法：回顾性分析1994～2003年收治的T3期声门上癌70例，均行喉功能保留手术，其中喉声门上水平部分切除术42例，喉声门上水平垂直部分切除术19例，喉环状软骨上部分切除术8例，喉近全切除术1例。以胸骨舌骨肌肌筋膜瓣、颈阔肌肌皮瓣、双蒂接力肌甲状软骨膜瓣、甲状软骨膜瓣等修复喉腔组织缺损，重建喉功能。全部患者均接受术后放疗（剂量50～60Gy）。结果：3年生存率为79．2％，5年生存率为68．4％。70例患者中已拔管60例，拔管率为85．7％。全部患者均恢复经口进食，无明显呛咳及吞咽困难。所有患者均发声成功，无一例因喉腔闭锁而致发声失败。结论：T3期声门上癌虽属晚期喉癌，但只要严格掌握适应证，熟练运用多种修复方法，提高外科手术技巧，保留喉功能是可行的。     

喉环状软骨上部分切除术治疗喉声门上型癌

目的:总结喉环状软骨上部分切除术治疗喉声门上型癌的疗效。方法:对32例接受喉环状软骨上部分切除术(环状软骨舌骨固定术) 治疗的喉声门上型癌病例进行随访和回顾性分析。结果:本组T2、 T3病例的3年生存率分别为85．7％(18／21)和66．6％(2／3),T2、 T3病例的5年生存率分别为83．3％(5／6)和50％(1,2);所有患者术后都能发音,发音比较粗或沙哑,但能听懂;所有患者术后都有不同程度的误咽,经过练习96．8％的患者误咽克服,1例患者 (3％)因术后始终无法克服误咽,改为喉全切除术;拔管率为 100％。结论:喉环状软骨上部分切除术手术操作简便,术后肿瘤学结果和功能结果满意,是治疗侵犯一侧或两侧声带的喉声门上型癌的有效术式。参8     

Analysis of curative effects on laryngeal carcinoma patients in the northeast region of China

CONCLUSIONS: In the past 20 years, the level of laryngeal carcinoma treatment in our country has been significantly improved. Early diagnosis is the key for increasing the ratio of larynx preservation surgeries and improving survival rates. The main causes of death within 5 years are local recurrence and metastasis. OBJECTIVE: To describe the main treatment methods for laryngeal carcinoma in China in the 1980s and 1990s and their prospective effects and investigate the prognostic factors. PATIENTS AND METHODS: A retrospective investigation was performed on the 1115 laryngeal carcinoma patients receiving treatment in the department of ENT of the First Affiliated Hospital of China Medical University during 1983-1996 and the survival rates and causes of death were analyzed statistically. RESULTS: There were 780 patients surviving for more than 5 years, 260 dead patients, and 75 patients lost to follow-up. According to the cumulative survival rate curve, the 5-year survival rate was 77% (94% for stage I, 89% for stage II, 82% for stage III, and 66% for stage IV). Glottic cancer has the highest 5-year survival rate, followed by supraglottic cancer, subglottic cancer, and transglottic cancer. The 5-year survival rate of patients receiving partial laryngectomy was 85%, while the 5-year survival rate of those receiving total laryngectomy was 68%. The leading causes of death within 5 years were local recurrence and metastasis (70%), and the causes of death were unknown in 14% of cases.     

303例下咽癌的外科治疗及组织移植修复重建术的临床分析

目的探讨下咽癌的外科治疗及术后下咽食管缺损不同组织移植Ⅰ期重建方法在下咽癌治疗中的远期疗效。方法回顾性分析1965～1998年外科治疗下咽癌患者303例，其中130例经不同组织移植重建下咽食管手术治疗(1997年UICC分期：Ⅱ期5例；Ⅲ期16例；Ⅳ期109例)，其中梨状窝区94例，咽后壁区18例，环后区18例。游离空肠15例，胃代下咽食管81例，结肠代下咽食管10例，胸大肌肌皮瓣修复20例，其他方法4例。173例下咽癌患者不需要重建(Ⅰ期7例，Ⅱ期12例，Ⅲ期51例，Ⅳ期103例)，其中梨状窝160例，咽后壁8例，环后5例。结果Kaplan-Meire法统计生存率，130例组织移植重建患者3年生存率为43．2％，5年生存率为36．4％；173例不需要组织重建患者3年生存率为59．2％，5年生存率为47．7％。各组吞咽功能良好率均在80％，以上。胃代下咽食管手术死亡率为8．6％(7／81例)；胸大肌肌皮瓣修复手术死亡率15．0％，(3／209例)；游离空肠及结肠代食管下咽无手术死亡。总手术并发症20世纪90年代之前为44．3％(35／79例)，90年代手术并发症为13．7％(7／51例)，x^2=13．457，P=0．004，差异有显著性；其中90年代胸大肌肌皮瓣修复并发症最高为18．2％(2／11例)。结论游离空肠、胃代下咽食管、胸大肌肌皮瓣修复在下咽癌的生存率、吞咽功能的恢复及手术并发症等方面均取得较好的治疗效果，是值得提倡的重建方法。     

鼻中隔恶性肿瘤的手术径路探讨

目的:探讨鼻中隔恶性肿瘤的手术径路。方法:16例中,鼻侧切开术8例、鼻内镜下手术5例、面中部揭翻术2例、经腭入路1例。并对其病理学特征、手术径路及预后进行回顾性分析。结果:16例中,鼻中隔鳞状细胞癌7例、腺样囊性癌4例、恶性黑色素瘤3例、腺癌1例、黏液表皮样癌1例。术后随访1~10年,其中失访1例,死亡2例,带瘤生存3例,无瘤生存10例。病死率为12.5%,带瘤生存率为18.8%,无瘤生存率为62.5%。结论:鼻中隔恶性肿瘤手术径路应根据病变范围、患者年龄采取不同的术式。如病变局限于鼻中隔前下部或后部,则鼻内镜下切除;如病变涉及鼻中隔全部或累及鼻腔其他部位,则以鼻侧切开为宜;若患者年龄较小,则以面中部揭翻或经腭入路为宜。     

用硅橡胶管重建下咽及颈段食管缺损

目的 重建下咽及颈段食管癌切除后缺损和治疗该部位的痕疤性狭窄和咽瘘。方法 采用自行研制的医用硅橡胶管进行重建。在动物实验和１例患者病理学检查中，可见术后缺损处网芽表面上皮化，形成新的管腔。结果 应用于下咽及颈段食管癌２５例，良性狭窄及咽瘘修补５例中，术后并发咽瘘６例（２０．０％）。随访５个月￣４年（平均２．５年），已拔除硅橡胶管２５例，恢复吞咽功能及正常饮食２３例，再度发生狭窄２例；现带管观察２例     

桥本病并发甲状腺癌的诊断和外科治疗

目的探讨桥本病并发甲状腺癌的诊断及手术方法。方法回顾性分析1982—1998年手术治疗的182例桥本病，其中合并甲状腺癌18例，对其术前检查和诊断及治疗经验进行分析研究。结果桥本病并发甲状腺癌发病率约为9．9％(18／182)，术前诊断率仅为33．3％(6／18)。采取了不同的手术方式，其中7例行Ⅱ期手术，5例局部扩大切除，2例加行同侧颈部清扫术。发现残余癌2例(20．0％)，甲状腺癌分化型的远期生存率(88．2％)远高于未分化型(0)，但统计学处理差异无显著性意义(P=0．167)，可能与病例数少有关。经随访，局部复发2例、转移2例，经再次手术均存活。5年生存率88．9％(16／18)，10年生存率81．3％(13／16)，3例死于远处转移。术后甲状腺机能减退6例，一侧声带麻痹3例，低钙抽搐3例。结论桥本病并发甲状腺癌肿术前确诊率低，病史、细针针吸活检、CT等综合分析有利于术前诊断，手术是其最有效的治疗方法。     

Clinical study of early laryngeal cancer

We retrospectively analyzed 71 consecutive cases of early laryngeal cancer (stage I or II) that had undergone primary treatment in our department between 1999 and 2004. There were 68 males and 3 females, and their ages ranged from 40 to 85 years of age (average; 67.7 years). Eight patients had the supraglottic type, 61 had the glottic type, and 2 had the subglottic type. Chemoradiotherapy was performed as the primary treatment except in the patients with glottic T1a cancer, who received radiotherapy alone. The 5-year survival rates was 91.1% for glottic cancer (T1a: 100%, T1b: 92.3%, T2: 85.8%) and 75.0% for supraglottic cancer. The local control rate of glottic cancer was 79.6% (T1a: 80.0%, T1b: 74.0%, T2: 85.2%), and significantly higher than that of supraglottic cancer (56.2%, p < 0.05). The laryngeal preservation rate was 84.4% in glottic cancer (T1a: 100%, T1b: 76.9%, T2: 77.5%) and 58.3% in supraglottic cancer, and the difference between T1a and T2 glottic cancer was significant (p < 0.05). Local recurrence and cervical lymph node metastasis were seen in 9 patients and 6 patients, respectively. Distant metastasis occurred in 4 patients, all of whom had the glottic type. Four patients died of their disease, and distant metastasis was the major cause of death in 3 of them. These results indicate that additional treatment should be performed in cases in which radiotherapy/chemoradiotherapy is ineffective and that both in the early stages glottic and supraglottic cancers can be successfully treated by radiotherapy/chemoradiotherapy. The results also suggested that the survival of patients with early laryngeal cancer depends on whether they develop distant metastasis. Introduction of adjuvant chemotherapy to improve their prognosis remains to be assessed.     

Multiple primary cancers of oral cavity and pharynx

Multiple primary cancers were found in 23 of 68 patients (34%) with an index cancer in the oral cavity or pharyngeal area treated in our institute from June 1995 to July 1998. Four cases had triple primary cancers. All 68 cases underwent upper and lower gastrointestinal endoscopy as well as ultrasonography of the liver. Lung CT was performed in cases with abnormal findings on chest roentgenograms. Multiple cancers were found in 5 of 25 oral cavity cases (20%), 6 of 14 mesopharynx cases (43%) and 12 of 29 hypopharynx cases (41%). Nine of 23 cases (39%) were synchronous and 14 (61%) were metachronous. Eighteen of 27 (69%) secondary cancers occurred in the upper aerodigestive tract with an especially high incidence (22%) in the esophagus. Gastroendoscopy also revealed 7 neoplastic lesions, aside from cancers, with the total abnormal rate of 24% (24/68). Thus, gastroendoscopy is useful for the diagnosis of multiple primary cancers. The frequency of multiple primary cancers in males (33%) was not different from that in females (35%). The average age of multiple primary cancer patients (65.1 years) was a little higher than that of single cancer patient (62.7 years). Smoking or drinking was not related to the incidence of multiple cancers. The interval between the first and the second cancer in metachronous cancer cases was 25.5 months on average, and within 4 years in 71% (10/14) of the cases. This result suggests that close follow-up including endoscopy should be required for at least 4 years after treatment of oral or pharyngeal cancer. Radical treatment for each of the multiple cancer lesions was performed in 22 of 23 cases, and the mortality rate of multiple primary cancer cases was not significantly different from that of single cancer cases. Among 7 cases who died of disease, 5 cases died of distant metastasis, suggesting that control of distant metastasis is an important issue in the treatment of multiple primary cancers.     

下咽癌累及颈段食管的处理

目的总结下咽癌累及颈段食管的处理经验。方法回顾性分析1989年—2000年48例累及颈段食管的下咽癌患者的手术治疗情况，其中男38例，女10例；年龄26～71岁，平均54．3岁。梨状窝癌33例，下咽后壁区癌14例，环后癌1例，均无远处转移。根据UICC1997年TNM分期标准均为T4M0期，其中cN0 28例，cNl 15例，cN2 5例。喉全切除术8例，喉部分切除残喉气管瓣修复下咽17例，23例保留了喉功能。所有病例均行改良性颈清扫术，其中单侧清扫38例，双侧清扫10例。患侧甲状腺叶切除42例。下咽食管缺损的修复方法分别为：喉气管瓣修复11例，胸大肌肌皮瓣13例，喉气管瓣＋胸大肌肌皮瓣6例，裂层皮片＋胸大肌肌皮瓣10例，胃上提咽胃吻合3例，结肠上徙5例。术后均接受放射治疗，剂量为55—75Gy。结果手术证实颈部淋巴结转移20例病理诊断；高分化鳞状细胞癌18例，中分化鳞状细胞癌24例，低分化鳞状细胞癌6例。术后并发症包括胸部刀口裂开1例，咽瘘10例。直接法计算生存率，失访2例以死亡计。全组患者3、5年生存率分别为52．1％（25／48）和27．3％（12／44）。保留喉功能组3、5年生存率分别为65．2％（15／23）和33．3％（7／21），不保留喉功能组3、5年生存率分别为40．0％（10／25）和21．7％（5／23）。23例保留了喉功能，15例患者拔除了气管套管，恢复了全部喉功能（发音、呼吸、吞咽保护），8例患者恢复了部分喉功能（发音、吞咽保护），拔管率为65．2％（15／23）。结论下咽癌累及颈段食管的处理以手术＋放疗的综合治疗为主，需行患侧颈清扫术，应尽量保留喉功能，无法保留喉功能时可以采用喉气管瓣或联合裂层皮片、胸大肌肌皮瓣修复下咽颈段食管缺损，颈段食管缺损较大时则采用胃或结肠代替。     

Therapeutic outcomes of laryngeal cancer at Kyoto University Hospital for 10 years

CONCLUSION: It is important to prevent regional lymph node recurrence and distant metastasis to achieve better survival of laryngeal cancer. OBJECTIVE: Therapeutic outcomes of 130 cases with laryngeal cancer treated at Kyoto University Hospital between 1995 and 2004 were reviewed. PATIENTS AND METHODS: In all, 121 males and 9 females were involved. Their ages ranged from 40 years to 92 years (average 66 years). All tumors were squamous cell carcinoma - arising at the glottis in 111 cases, the supraglottis in 18, and the subglottis in 1 case. Most glottic cancers (77.5%) were classified as stage I or II, while most supraglottic cancers (77.8%) were at stage III or IV. Stage I/II cancers were basically treated by conventional radiotherapy (60-66 Gy) and twice-daily hyperfractionated radiotherapy (70-74 Gy), respectively, attempting to preserve the larynx. Total laryngectomy with neck dissection was performed in the treatment of stage III/IV cases. RESULTS: Five-year disease-specific survival rates were 100%, 96%, 100%, and 68% for stage I, II, III, and IV, respectively. Five-year laryngeal preservation rates were 98%, 100%, 86%, 0%, and 0% for T1a, T1b, T2, T3, and T4 of glottic cancer, respectively. Local recurrence occurred in five cases of stage I/II glottic cancer, which was successfully salvaged. Regional lymph node recurrence occurred in five cases including four patients with glottic cancer and one with supraglottic cancer. Two of them died of disease despite undergoing salvage therapy. Distant metastasis occurred in the lung in four cases including one glottic and three supraglottic cancer patients after initial treatment.     

下咽癌颈淋巴转移相关因素的研究

目的研究下咽癌颈淋巴转移的特点、规律及对预后的影响。方法收集1985-2000年住院治疗下咽癌患者108例，均经手术治疗，且术前未行放疗和化疗。根据1992年国际抗癌联合会（UICC）分期标准进行分期分级。手术后将下咽癌及颈淋巴结标本进行病理观察，确定肿瘤主体所在原发部位及发生转移的颈淋巴结分布区域。按照病理学将肿瘤的病理分化程度确定为高、中、低分化。通过颈淋巴结病理检查和随访观察确定颈淋巴转移情况，用Kaplan-Meier方法对3、5年生存率进行非参数分析。结果病例中T1、T2淋巴结转移率为45．8％，T3、T4淋巴结转移率为79．8％，总的淋巴结转移率为75．0％（81／108），（P〈0．05）。梨状窝癌为100例，占全部病例的92．6％（100／108），梨状窝及下咽后壁癌的颈淋巴转移率分别为74．0％和87．5％（P〉0．05）。病理高、中、低分化型3组，其颈淋巴转移率分别为72．2％、67．6％、85．7％（P〉0．05）。患者3、5年累积生存率分为67．53％及29．87％。Ⅱ、Ⅲ区颈淋巴转移率为76．5％，Ⅴ、Ⅵ区颈淋巴转移率为8．6％。结论下咽癌颈淋巴转移率高。下咽癌颈淋巴转移是影响下咽癌的预后主要因素，随着颈淋巴转移程度的增加，患者3、5年生存率逐渐降低。